Trial reportBMC cancer2012
WRAP53 is an independent prognostic factor in rectal cancer- a study of Swedish clinical trial of preoperative radiotherapy in rectal cancer patients.
Trial report in BMC cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 36 citations in OpenAlex.
- Low levels of WRAP53 predict decreased efficacy of radiotherapy and are prognostic for local recurrence and death from breast cancer: a long-term follow-up of the SweBCG91RT randomized trial.Molecular oncology · 2023Trial
- The role of the WD40-repeat protein family in cancer.Molecular cancer · 2026Review
- WRAP53 is Downregulated in Acute Myeloid Leukemia Patients and Positively Correlates With HTERT Expression.Cancer reports (Hoboken, N.J.) · 2026Article
- Predicting patient outcomes with gene-expression biomarkers from colorectal cancer organoids and cell lines.Frontiers in molecular biosciences · 2025Article
- The Role of WRAP53 in Cell Homeostasis and Carcinogenesis Onset.Current issues in molecular biology · 2022Review
- Evaluation of dyskerin expression and the Cajal body protein WRAP53β as potential prognostic markers for patients with primary vaginal carcinoma.Oncology letters · 2022Article
- Telomerase (Genes · 2021Article
- Suppression of TCAB1 expression induced cellular senescence by lessening proteasomal degradation of p21 in cancer cells.Cancer cell international · 2021Article
- Article
- Prognostic value of nuclear FBI-1 in patients with rectal cancer with or without preoperative radiotherapy.Oncology letters · 2019Article
- Expression of WDR79 is associated withJournal of Cancer · 2019Article
- The Cajal Body Protein WRAP53β Prepares the Scene for Repair of DNA Double-Strand Breaks by Regulating Local Ubiquitination.Frontiers in molecular biosciences · 2019Review
- Promoter methylation ofOncology letters · 2018Article
- Oncogenic Activity of Wrap53 in Human Colorectal Cancer In Vitro and in Nude Mouse Xenografts.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- DNA Methylation of Telomere-Related Genes and Cancer Risk.Cancer prevention research (Philadelphia, Pa.) · 2018Article
- WDR79 mediates the proliferation of non-small cell lung cancer cells by regulating the stability of UHRF1.Journal of cellular and molecular medicine · 2018Article
- CBD: a biomarker database for colorectal cancer.Database : the journal of biological databases and curation · 2018Article
- Epstein-Barr virus-induced up-regulation of TCAB1 is involved in the DNA damage response in nasopharyngeal carcinoma.Scientific reports · 2017Article
- Phosphorylation of the Cajal body protein WRAP53β by ATM promotes its involvement in the DNA damage response.RNA biology · 2017Article
- WDR79 promotes the proliferation of non-small cell lung cancer cells via USP7-mediated regulation of the Mdm2-p53 pathway.Cell death & disease · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExpression of WRAP53 protein has oncogenic properties and it is up regulated in several types of tumors.
methodsWe examined expression of WRAP53 protein in rectal cancers and analyzed its relationship to the response to preoperative radiotherapy and patient survival. The WRAP53 protein was examined by immunohistochemistry in normal mucosa, primary tumors and lymph node metastases from 143 rectal cancer patients participated in a Swedish clinical trial of preoperative radiotherapy.
resultsFrequency of WRAP53 protein expression was increased in primary rectal cancer compared to the normal mucosa (p<0.05). In non-radiotherapy group positive WRAP53 in primary tumors (p=0.03, RR, 3.73, 95% CI, 1.13-11.89) or metastases (p=0.01, RR, 4.11, 95% CI, 1.25-13.14), was associated with poor prognosis independently of stages and differentiations. In radiotherapy group, positive WRAP53 in the metastasis correlated with better survival (p=0.04). An interaction analysis showed that the correlations of WRAP53 with the prognostic significance with and without radiotherapy in the metastasis differed (p=0.01). In the radiotherapy group, expression of WRAP53 in metastases gave a better outcome (p=0.02, RR, 0.32, 95% CI, 0.13-0.84), and an interaction analysis showed significance between the two groups (p=0.01).
conclusionWRAP53 may be a new biomarker used to predict prognosis and to select suitable patients for preoperative radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.